Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameThioridazine
Accession NumberDB00679  (APRD00596)
Typesmall molecule
Groupsapproved
Description

A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618)

Structure
Thumb
Synonyms
SynonymLanguageCode
ThioridazinNot AvailableNot Available
Salts
Name/CAS Structure Properties
Thioridazine Hydrochloride
130-61-0
Thumb
  • InChI Key: NZFNXWQNBYZDAQ-UHFFFAOYNA-N
  • Monoisotopic Mass: 406.130417961
  • Average Mass: 407.035
DBSALT000503
Brand names
NameCompany
AldazineNot Available
MallorolNot Available
MelerilNot Available
MellarilNot Available
MelleretteNot Available
MellerettenNot Available
MellerilNot Available
NovoridazineNot Available
RidazinNot Available
RidazineNot Available
SonapaxNot Available
ThiorilNot Available
Brand mixturesNot Available
Categories
CAS number50-52-2
WeightAverage: 370.575
Monoisotopic: 370.153740222
Chemical FormulaC21H26N2S2
InChI KeyInChIKey=KLBQZWRITKRQQV-UHFFFAOYSA-N
InChI
InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
IUPAC Name
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine
SMILES
CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1
Mass Specshow(8.15 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassHeterocyclic Compounds
ClassBenzothiazines
SubclassPhenothiazines
Direct parentPhenothiazines
Alternative parentsBenzene and Substituted Derivatives; Piperidines; Tertiary Amines; Polyamines; Thioethers
Substituentspiperidine; benzene; tertiary amine; thioether; polyamine; amine; organonitrogen compound
Classification descriptionThis compound belongs to the phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Pharmacology
IndicationFor the treatment of schizophrenia and generalized anxiety disorder.
PharmacodynamicsThioridazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Thioridazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of actionThioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Absorption60%
Volume of distributionNot Available
Protein binding95%
Metabolism

Hepatic

Route of eliminationNot Available
Half life21-25 hours
ClearanceNot Available
ToxicityLD50=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9068
Blood Brain Barrier + 0.9901
Caco-2 permeable + 0.7912
P-glycoprotein substrate Substrate 0.7863
P-glycoprotein inhibitor I Inhibitor 0.8564
P-glycoprotein inhibitor II Inhibitor 0.9115
Renal organic cation transporter Inhibitor 0.7943
CYP450 2C9 substrate Non-substrate 0.7981
CYP450 2D6 substrate Substrate 0.8919
CYP450 3A4 substrate Non-substrate 0.5068
CYP450 1A2 substrate Inhibitor 0.9106
CYP450 2C9 substrate Non-inhibitor 0.908
CYP450 2D6 substrate Inhibitor 0.8932
CYP450 2C19 substrate Non-inhibitor 0.7697
CYP450 3A4 substrate Non-inhibitor 0.8308
CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5826
Ames test Non AMES toxic 0.8703
Carcinogenicity Non-carcinogens 0.9528
Biodegradation Not ready biodegradable 1.0
Rat acute toxicity 2.5395 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.906
hERG inhibition (predictor II) Inhibitor 0.8384
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Hi tech pharmacal co inc
  • Pharmaceutical assoc inc div beach products
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Wockhardt eu operations (swiss) ag
  • Roxane laboratories inc
  • Ivax pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
SolutionOral
SuspensionOral
TabletOral
Prices
Unit descriptionCostUnit
Thioridazine hcl powder11.16USDg
Thioridazine HCl 200 mg tablet1.14USDtablet
Thioridazine HCl 150 mg tablet1.01USDtablet
Thioridazine HCl 100 mg tablet0.69USDtablet
Thioridazine 100 mg tablet0.67USDtablet
Thioridazine HCl 50 mg tablet0.61USDtablet
Thioridazine 50 mg tablet0.58USDtablet
Thioridazine HCl 25 mg tablet0.49USDtablet
Thioridazine 25 mg tablet0.47USDtablet
Thioridazine HCl 15 mg tablet0.45USDtablet
Thioridazine HCl 10 mg tablet0.35USDtablet
Thioridazine 10 mg tablet0.33USDtablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point73 °CPhysProp
boiling point230 °C at 2.00E-02 mm HgPhysProp
water solubility0.0336 mg/LNot Available
logP5.90HANSCH,C ET AL. (1995)
pKa9.5EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
water solubility8.55e-04 g/lALOGPS
logP5.93ALOGPS
logP5.47ChemAxon
logS-5.6ALOGPS
pKa (strongest basic)8.93ChemAxon
physiological charge1ChemAxon
hydrogen acceptor count2ChemAxon
hydrogen donor count0ChemAxon
polar surface area6.48ChemAxon
rotatable bond count4ChemAxon
refractivity113.52ChemAxon
polarizability43.26ChemAxon
number of rings4ChemAxon
bioavailability1ChemAxon
rule of fiveNoChemAxon
Ghose filterYesChemAxon
Veber's ruleYesChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD00373
PubChem Compound5452
PubChem Substance46509070
ChemSpider5253
ChEBI9566
ChEMBLCHEMBL479
Therapeutic Targets DatabaseDAP000476
PharmGKBPA451666
IUPHAR100
Guide to Pharmacology100
Drug Product Database360244
RxListhttp://www.rxlist.com/cgi/generic3/thioridazine.htm
Drugs.comhttp://www.drugs.com/cdi/thioridazine.html
WikipediaThioridazine
ATC CodesN05AC02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(44.7 KB)
Interactions
Drug Interactions
Drug
AbirateroneAbiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely.
AmiodaroneIncreased risk of cardiotoxicity and arrhythmias
AmitriptylineIncreased risk of cardiotoxicity and arrhythmias
AmphetamineDecreased anorexic effect, may increase psychotic symptoms
ArtemetherAdditive QTc-prolongation may occur. Concomitant therapy is contraindicated.
AsenapineThioridazine is a CYP2D6 substrate in which concomitant therapy with asenapine will increase serum levels of thioridazine. Consider alternative therapy.
AstemizoleIncreased risk of cardiotoxicity and arrhythmias
AtomoxetineThe CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
BenzphetamineAntipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
BenzylpenicillinIncreased risk of cardiotoxicity and arrhythmias
BretyliumIncreased risk of cardiotoxicity and arrhythmias
BromocriptineThe phenothiazine decreases the effect of bromocriptine
BupropionBupropion may increase the effect and toxicity of thioridazine.
ChloroquineIncreased risk of cardiotoxicity and arrhythmias
ChlorpromazineIncreased risk of cardiotoxicity and arrhythmias
CisaprideIncreased risk of cardiotoxicity and arrhythmias
CrizotinibConcurrent use with drugs that prolong QTc interval is contraindicated.
DexfenfluramineDecreased anorexic effect, may increase psychotic symptoms
DextroamphetamineDecreased anorexic effect, may increase psychotic symptoms
DiethylpropionDecreased anorexic effect, may increase psychotic symptoms
DiltiazemIncreased risk of cardiotoxicity and arrhythmias
DiphenhydramineIncreased risk of cardiotoxicity and arrhythmias
DisopyramideIncreased risk of cardiotoxicity and arrhythmias
DofetilideIncreased risk of cardiotoxicity and arrhythmias
DonepezilPossible antagonism of action
DoxepinIncreased risk of cardiotoxicity and arrhythmias
DuloxetineIncreased risk of cardiotoxicity and arrhythmias
ErythromycinIncreased risk of cardiotoxicity and arrhythmias
FenfluramineDecreased anorexic effect, may increase psychotic symptoms
FlecainideIncreased risk of cardiotoxicity and arrhythmias
FluoxetineIncreased risk of cardiotoxicity and arrhythmias
FluvoxamineIncreased risk of cardiotoxicity and arrhythmias
GalantaminePossible antagonism of action
GatifloxacinIncreased risk of cardiotoxicity and arrhythmias
GrepafloxacinIncreased risk of cardiotoxicity and arrhythmias
GuanethidineThioridazine may decrease the effect of guanethidine.
HalofantrineIncreased risk of cardiotoxicity and arrhythmias
HaloperidolIncreased risk of cardiotoxicity and arrhythmias
ImipramineIncreased risk of cardiotoxicity and arrhythmias
JosamycinIncreased risk of cardiotoxicity and arrhythmias
LevofloxacinIncreased risk of cardiotoxicity and arrhythmias
LorcaserinAvoid combination.The combination is likely to reduce the metabolism of Thioridazine.
LumefantrineAdditive QTc-prolongation may occur. Concomitant therapy should be avoided.
MaprotilineIncreased risk of cardiotoxicity and arrhythmias
MazindolDecreased anorexic effect, may increase psychotic symptoms
MethamphetamineDecreased anorexic effect, may increase psychotic symptoms
MetrizamideIncreased risk of convulsions
Mirabegron Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely.
ParoxetineIncreased risk of cardiotoxicity and arrhythmias
PentamidineIncreased risk of cardiotoxicity and arrhythmias
PhendimetrazineDecreased anorexic effect, may increase psychotic symptoms
PhenmetrazineDecreased anorexic effect, may increase psychotic symptoms
PhentermineDecreased anorexic effect, may increase psychotic symptoms
PhenylpropanolamineDecreased anorexic effect, may increase psychotic symptoms
PimozideIncreased risk of cardiotoxicity and arrhythmias
PindololIncreased risk of cardiotoxicity and arrhythmias
ProcainamideIncreased risk of cardiotoxicity and arrhythmias
PropafenoneIncreased risk of cardiotoxicity and arrhythmias.
PropranololIncreased risk of cardiotoxicity and arrhythmias
QuinidineIncreased risk of cardiotoxicity and arrhythmias
Quinidine barbiturateIncreased risk of cardiotoxicity and arrhythmias
QuinineIncreased risk of cardiotoxicity and arrhythmias
RanolazinePossible additive effect on QT prolongation
RivastigminePossible antagonism of action
SertindoleIncreased risk of cardiotoxicity and arrhythmias
SotalolIncreased risk of cardiotoxicity and arrhythmias
SparfloxacinIncreased risk of cardiotoxicity and arrhythmias
SpiramycinIncreased risk of cardiotoxicity and arrhythmias
TacrineThe therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thioridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
TacrolimusMay cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
TamoxifenThioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
TamsulosinThioridazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Thioridazine is initiated, discontinued, or dose changed.
TelithromycinTelithromycin may increase the QTc-prolonging effect of Thioridazine. Concomitant therapy should be avoided.
TerbinafineTerbinafine may increase serum concentrations of Thioridazine. Concomitant therapy is contraindicated.
TerfenadineIncreased risk of cardiotoxicity and arrhythmias
TetrabenazineMay cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
ThiothixeneMay cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
TiclopidineTiclopidine may decrease the metabolism of thioridazine. Concomitant therapy is contraindicated.
ToremifeneMay cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
TramadolThioridazine may decrease the effect of Tramadol by decreasing active metabolite production.
TranylcypromineTranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Thioridazine. Concomitant therapy is contraindicated.
TrimethobenzamideTrimethobenzamide and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
TrimipramineMay cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
TriprolidineThe antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Thioridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
TrospiumTrospium and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
VilazodoneThioridazine prescribing information contraindicates the concomitant use of agents that inhibit CYP2D6 isoenzymes. Avoid combination.
VoriconazoleAdditive QTc prolongation may occur. Concomitant use is contraindicated.
VorinostatAdditive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
ZiprasidoneAdditive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
ZuclopenthixolAdditive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.
Zuclopenthixol acetateAdditive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.
Zuclopenthixol decanoateAdditive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.
Food InteractionsNot Available

1. D(2) dopamine receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
D(2) dopamine receptor P14416 Details

References:

  1. Seeman P: Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand Suppl. 1990;358:14-20. Pubmed
  2. Assie MB, Sleight AJ, Koek W: Biphasic displacement of [3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. Eur J Pharmacol. 1993 Jun 24;237(2-3):183-9. Pubmed
  3. Dimpfel W, Spuler M, Wessel K: Different neuroleptics show common dose and time dependent effects in quantitative field potential analysis in freely moving rats. Psychopharmacology (Berl). 1992;107(2-3):195-202. Pubmed
  4. Barth VN, Chernet E, Martin LJ, Need AB, Rash KS, Morin M, Phebus LA: Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci. 2006 May 22;78(26):3007-12. Epub 2006 Jan 24. Pubmed
  5. Carey GJ, Bergman J: Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psychopharmacology (Berl). 1997 Aug;132(3):261-9. Pubmed

2. D(1A) dopamine receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
D(1A) dopamine receptor P21728 Details

References:

  1. Hammock RG, Schroeder SR, Levine WR: The effect of clozapine on self-injurious behavior. J Autism Dev Disord. 1995 Dec;25(6):611-26. Pubmed

3. Alpha-1A adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1A adrenergic receptor P35348 Details

References:

  1. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. Pubmed
  2. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. Pubmed

4. Alpha-1B adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1B adrenergic receptor P35368 Details

References:

  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. Pubmed

5. 5-hydroxytryptamine receptor 2A

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2A P28223 Details

References:

  1. Andree TH, Mikuni M, Tong CY, Koenig JI, Meltzer HY: Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex. J Neurochem. 1986 Jan;46(1):191-7. Pubmed
  2. Canton H, Verriele L, Millan MJ: Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci Lett. 1994 Nov 7;181(1-2):65-8. Pubmed
  3. Burki HR: Binding of psychoactive drugs to rat brain amine receptors, measured ex vivo, and their effects on the metabolism of biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1986 Mar;332(3):258-66. Pubmed
  4. Costall B, Naylor RJ: Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Br J Pharmacol. 1995 Dec;116(7):2989-99. Pubmed
  5. Morisset S, Sahm UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz JC: Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther. 1999 Feb;288(2):590-6. Pubmed

6. Potassium voltage-gated channel subfamily H member 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Potassium voltage-gated channel subfamily H member 2 Q12809 Details

References:

  1. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC: hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656. Biochem Biophys Res Commun. 2006 Dec 8;351(1):273-80. Epub 2006 Oct 23. Pubmed

1. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. Pubmed
  2. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2E1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11